ASCO 2020 | Updates from the Phase III KEYNOTE-061 trial

Charles Fuchs, MD, MPH, Yale Cancer Center, New Haven, CT discusses the results of the phase III KEYNOTE-61 study (NCT02370498) which aims to compared response rates to either pembrolizumab or paclitaxel in PDL1 positive, gastric cancer patients. Dr Fuch continues on to explore the importance of tumour mutational burden as a marker for response to immune checkpoint blockade therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).